{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:54:03Z","timestamp":1791050043578,"version":"4.1.0"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.pharmthera.2020.107624","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T17:47:57Z","timestamp":1593971277000},"page":"107624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Cyclooxygenases and the cardiovascular system"],"prefix":"10.1016","volume":"217","author":[{"given":"Jane A.","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Kirkby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blerina","family":"Ahmetaj-Shala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Crescente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Lopes Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky","family":"Vaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107624_bb0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","article-title":"Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo","volume":"3","author":"Goldstein","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Coxib, traditional, N. T. C","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0015","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCULATIONAHA.114.011591","article-title":"Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: Novel explanation of cardiovascular side effects associated with anti-inflammatory drugs","volume":"131","author":"Ahmetaj-Shala","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0021-9150(88)90087-1","article-title":"Stable analogues of prostacyclin and thromboxane A2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. The effect of calcium antagonists","volume":"72","author":"Akopov","year":"1988","journal-title":"Atherosclerosis"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107624_bb0025","first-page":"S21","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2019\/20: G protein-coupled receptors","volume":"176","author":"Alexander","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0030","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0035","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/ATVBAHA.109.193367","article-title":"PPARbeta\/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association\/repression of PKCalpha--brief report","volume":"29","author":"Ali","year":"2009","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0040","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1161\/01.CIR.81.6.1784","article-title":"Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris","volume":"81","author":"Aoyama","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0045","first-page":"229","article-title":"Transcription from TATA-less promoters: Dihydrofolate reductase as a model","volume":"3","author":"Azizkhan","year":"1993","journal-title":"Critical Reviews in Eukaryotic Gene Expression"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0050","doi-asserted-by":"crossref","first-page":"FSO236","DOI":"10.4155\/fsoa-2017-0067","article-title":"Omega-3 fatty acids in atherosclerosis and coronary artery disease","volume":"3","author":"Back","year":"2017","journal-title":"Future Sci OA"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0055","first-page":"S324","article-title":"Prostacyclin, thromboxane A2 and calcium antagonists: Effects on atherosclerotic characteristics of vascular cells","volume":"47","author":"Baldenkov","year":"1988","journal-title":"Biomedica Biochimica Acta"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0060","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0065","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1476-5381.2009.00373.x","article-title":"Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease","volume":"158","author":"Belvisi","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1113\/jphysiol.1989.sp017630","article-title":"Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm","volume":"412","author":"Benjamin","year":"1989","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0075","article-title":"A review on mPGES-1 inhibitors: From preclinical studies to clinical applications","volume":"147","author":"Bergqvist","year":"2019","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11883-015-0507-8","article-title":"Nuclear receptors in vascular biology","volume":"17","author":"Bishop-Bailey","year":"2015","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0090","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/gut.27.11.1292","article-title":"Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine","volume":"27","author":"Bjarnason","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.prostaglandins.2006.06.005","article-title":"Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease","volume":"80","author":"Blardi","year":"2006","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0100","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0024-3205(98)00197-0","article-title":"Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells","volume":"62","author":"Bryant","year":"1998","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0105","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1042\/BST20160474","article-title":"Omega-3 fatty acids and inflammatory processes: From molecules to man","volume":"45","author":"Calder","year":"2017","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1113\/jphysiol.1987.sp016651","article-title":"The role of myogenic relaxation, adenosine and prostaglandins in human forearm reactive hyperaemia","volume":"389","author":"Carlsson","year":"1987","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0090-6980(83)90092-8","article-title":"Effect of different prostaglandin synthesis inhibitors on post-occlusive blood flow in human forearm","volume":"26","author":"Carlsson","year":"1983","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0120","doi-asserted-by":"crossref","first-page":"13926","DOI":"10.1073\/pnas.162468699","article-title":"COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic\/antipyretic drugs: Cloning, structure, and expression","volume":"99","author":"Chandrasekharan","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2018.01.001","article-title":"Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials","volume":"129","author":"Chang","year":"2018","journal-title":"Prostaglandins, Leukotrienes, and Essential Fatty Acids"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/shk.0b013e318033ebc5","article-title":"Role of bacterial endotoxin in chronic heart failure: The gut of the matter","volume":"28","author":"Charalambous","year":"2007","journal-title":"Shock"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0135","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00005344-200003000-00022","article-title":"Effect of stable fish oil on arterial thrombogenesis, platelet aggregation, and superoxide dismutase activity","volume":"35","author":"Chen","year":"2000","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0140","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1172\/JCI27540","article-title":"Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function","volume":"116","author":"Cheng","year":"2006","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0090-6980(81)90213-6","article-title":"Prostacyclin is not a circulating hormone","volume":"22","author":"Christ-Hazelhof","year":"1981","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0150","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bph.14196","article-title":"Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond)","volume":"176","author":"Crescente","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0155","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.7150\/ijms.27238","article-title":"The pivotal role of Thymus in atherosclerosis mediated by immune and inflammatory response","volume":"15","author":"Dai","year":"2018","journal-title":"International Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0160","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00000542-200502000-00026","article-title":"Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans","volume":"102","author":"Dembo","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nri3859","article-title":"Eicosanoid storm in infection and inflammation","volume":"15","author":"Dennis","year":"2015","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0170","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/14656566.2019.1609942","article-title":"Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia","volume":"20","author":"Doggrell","year":"2019","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1476-5381.1978.tb17307.x","article-title":"Recirculation of prostacyclin (PGI2) in the dog","volume":"64","author":"Dusting","year":"1978","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0180","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1152\/jappl.1996.81.4.1807","article-title":"Contribution of nitric oxide and prostaglandins to reactive hyperemia in human forearm","volume":"81","author":"Engelke","year":"1996","journal-title":"Journal of Applied Physiology (Bethesda, MD: 1985)"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/2042098617690485","article-title":"Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: Latest evidence and clinical implications","volume":"8","author":"Fanelli","year":"2017","journal-title":"Ther Advanced Drug Safety"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0190","first-page":"851","article-title":"Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication","volume":"62","author":"Florez","year":"2009","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0195","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0006-2952(76)90216-1","article-title":"The importance of phospholipase-A2 in prostaglandin biosynthesis","volume":"25","author":"Flower","year":"1976","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0200","first-page":"347","article-title":"Cardiovascular complications of non-steroidal anti-inflammatory drugs","volume":"35","author":"Fosslien","year":"2005","journal-title":"Annals of Clinical and Laboratory Science"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0205","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","article-title":"COX-2 inhibitors and cardiovascular risk","volume":"50","author":"Funk","year":"2007","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0210","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0165-6147(03)00077-4","article-title":"Prevention of thrombosis and vascular inflammation: Benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors","volume":"24","author":"de Gaetano","year":"2003","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0090-6980(02)00026-6","article-title":"The structures of prostaglandin endoperoxide H synthases-1 and -2","volume":"68-69","author":"Garavito","year":"2002","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0220","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1111\/bph.12986","article-title":"Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling","volume":"172","author":"Gong","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1096\/fj.201800355RRRR","article-title":"Integrated communications between cyclooxygenase-2 and Alzheimer\u2019s disease","volume":"33","author":"Guan","year":"2019","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1172\/JCI110639","article-title":"Prostacyclin modulates cholesteryl ester hydrolytic activity by its effect on cyclic adenosine monophosphate in rabbit aortic smooth muscle cells","volume":"70","author":"Hajjar","year":"1982","journal-title":"The Journal of Clinical Investigation"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107624_bb0235","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00005344-200605001-00007","article-title":"COX-2 and the kidney","volume":"47","author":"Harris","year":"2006","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0240","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1172\/JCI117620","article-title":"Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction","volume":"94","author":"Harris","year":"1994","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0245","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: A review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0250","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/318186a0","article-title":"Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man","volume":"318","author":"Heavey","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0255","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1475-097X.2008.00833.x","article-title":"The effect of glibenclamide on acetylcholine and sodium nitroprusside induced vasodilatation in human cutaneous microcirculation","volume":"29","author":"Hojs","year":"2009","journal-title":"Clinical Physiology and Functional Imaging"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020532","article-title":"The differential effects of Eicosapentaenoic acid and Docosahexaenoic acid on Cardiometabolic risk factors: A systematic review","volume":"19","author":"Innes","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0265","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00232201","article-title":"Interactions between the brain renin-angiotensin system and brain prostanoids in the control of vasopressin secretion","volume":"83","author":"Inoue","year":"1990","journal-title":"Experimental Brain Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0270","first-page":"1","article-title":"Modulators of platelet function in aging","author":"Iyer","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0275","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/adc.57.6.459","article-title":"Plasma prostacyclin from birth to adolescence","volume":"57","author":"Kaapa","year":"1982","journal-title":"Archives of Disease in Childhood"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0280","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.plipres.2007.01.001","article-title":"Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation","volume":"46","author":"Kang","year":"2007","journal-title":"Progress in Lipid Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174262","article-title":"Cyclo-Oxygenase (COX) inhibitors and cardiovascular risk: Are non-steroidal anti-inflammatory drugs really anti-inflammatory?","volume":"20","author":"Khan","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0290","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1021\/acs.biochem.7b01019","article-title":"Molecular mechanisms in the selectivity of nonsteroidal anti-inflammatory drugs","volume":"57","author":"Khan","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0295","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1113\/jphysiol.1976.sp011358","article-title":"Endogenous prostaglandins as local regulators of blood flow in man: Effect of indomethacin on reactive and functional hyperaemia","volume":"257","author":"Kilbom","year":"1976","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0300","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1073\/pnas.1517642113","article-title":"Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-kappaB and NFAT transcriptional pathways","volume":"113","author":"Kirkby","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0305","doi-asserted-by":"crossref","first-page":"17597","DOI":"10.1073\/pnas.1209192109","article-title":"Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system","volume":"109","author":"Kirkby","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098165","article-title":"COX-2 protects against atherosclerosis independently of local vascular prostacyclin: Identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks","volume":"9","author":"Kirkby","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0315","article-title":"Mechanistic definition of the cardiovascular mPGES-1\/COX-2\/ADMA axis","author":"Kirkby","year":"2019","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0320","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1096\/fj.15-275065","article-title":"Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation","volume":"29","author":"Kirkby","year":"2015","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069524","article-title":"LC-MS\/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression","volume":"8","author":"Kirkby","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.105.085431","article-title":"Acetaminophen and the cyclooxygenase-3 puzzle: Sorting out facts, fictions, and uncertainties","volume":"315","author":"Kis","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0335","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00011-006-0083-z","article-title":"Cloning of cyclooxygenase-1b (putative COX-3) in mouse","volume":"55","author":"Kis","year":"2006","journal-title":"Inflammation Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0340","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.08.004","article-title":"Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy","volume":"193","author":"Knowles","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0345","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000047814","article-title":"Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets","volume":"11","author":"Kobzar","year":"2001","journal-title":"Cellular Physiology and Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0350","first-page":"F460","article-title":"Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function","volume":"272","author":"Komhoff","year":"1997","journal-title":"The American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0355","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0090-6980(79)80049-0","article-title":"Effects of intracerebroventricular administration of prostaglandins I2, E2, F2 alpha and indomethacin on blood pressure in the rat","volume":"17","author":"Kondo","year":"1979","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0360","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1126\/science.1087344","article-title":"Transcriptional repression of atherogenic inflammation: Modulation by PPARdelta","volume":"302","author":"Lee","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0365","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.66.6.1299","article-title":"The interaction of sodium nitroprusside with human endothelial cells and platelets: Nitroprusside and prostacyclin synergistically inhibit platelet function","volume":"66","author":"Levin","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0370","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/1440-1681.12501","article-title":"Role of cyclooxygenase-1 and -2 in endothelium-dependent contraction of atherosclerotic mouse abdominal aortas","volume":"43","author":"Li","year":"2016","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0375","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1476-5381.1989.tb12674.x","article-title":"Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation","volume":"98","author":"Lidbury","year":"1989","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0380","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1161\/01.CIR.0000015365.49180.05","article-title":"Cyclooxygenase-1 and bicistronic cyclooxygenase-1\/prostacyclin synthase gene transfer protect against ischemic cerebral infarction","volume":"105","author":"Lin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0385","doi-asserted-by":"crossref","first-page":"F1133","DOI":"10.1152\/ajprenal.00604.2011","article-title":"Role of cyclooxygenase-1-mediated prostacyclin synthesis in endothelium-dependent vasoconstrictor activity of porcine interlobular renal arteries","volume":"302","author":"Liu","year":"2012","journal-title":"American Journal of Physiology. Renal Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0390","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2016.03.043","article-title":"The endothelial cyclooxygenase pathway: Insights from mouse arteries","volume":"780","author":"Luo","year":"2016","journal-title":"European Journal of Pharmacology"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107624_bb0395","first-page":"1843","article-title":"Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: The Standard care vs. Celecoxib Outcome Trial (SCOT)","volume":"38","author":"MacDonald","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0400","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0049-3848(98)90001-9","article-title":"Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin","volume":"49","author":"Macdonald","year":"1988","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0405","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.mayocp.2014.07.015","article-title":"Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: Contrasting interactions in the stomach and small intestine","volume":"89","author":"Marlicz","year":"2014","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0410","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/ard.62.6.501","article-title":"Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs","volume":"62","author":"Martel-Pelletier","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0420","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0021-9150(85)90091-7","article-title":"The influence of dietary fats on plasma lipids, blood pressure and coagulation indices in the rat","volume":"55","author":"McIntosh","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0425","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/S0021-9258(18)53294-4","article-title":"Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs","volume":"268","author":"Meade","year":"1993","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0430","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/156652411800615144","article-title":"Prostacyclin receptor regulation--from transcription to trafficking","volume":"11","author":"Midgett","year":"2011","journal-title":"Current Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0435","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5339\/gcsp.2014.53","article-title":"Role of prostacyclin in pulmonary hypertension","volume":"2014","author":"Mitchell","year":"2014","journal-title":"Global Cardiology Science Practice"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0440","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1073\/pnas.90.24.11693","article-title":"Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase","volume":"90","author":"Mitchell","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0445","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bph.14167","article-title":"Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system","volume":"176","author":"Mitchell","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0450","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/CIRCRESAHA.117.312144","article-title":"Kidney transplantation in a patient lacking cytosolic phospholipase A2 proves renal origins of urinary PGI-M and TX-M","volume":"122","author":"Mitchell","year":"2018","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0455","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCRESAHA.119.314927","article-title":"Cell-specific gene deletion reveals the antithrombotic function of COX1 and explains the vascular COX1\/prostacyclin paradox","volume":"125","author":"Mitchell","year":"2019","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0460","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/273767a0","article-title":"Prostacyclin is a circulating hormone","volume":"273","author":"Moncada","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0465","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/01.CIR.102.16.2005","article-title":"Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0470","first-page":"33","article-title":"Genetic polymorphisms of prostacyclin synthase gene and cardiovascular disease","volume":"29","author":"Nakayama","year":"2010","journal-title":"International Angiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0475","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0895-7061(00)01216-4","article-title":"Association of 5\u2032 upstream promoter region of prostacyclin synthase gene variant with cerebral infarction","volume":"13","author":"Nakayama","year":"2000","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0480","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0006-291X(02)02341-0","article-title":"Splicing mutation of the prostacyclin synthase gene in a family associated with hypertension","volume":"297","author":"Nakayama","year":"2002","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0485","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/00325481.2019.1607414","article-title":"The eicosapentaenoic acid: Arachidonic acid ratio and its clinical utility in cardiovascular disease","volume":"131","author":"Nelson","year":"2019","journal-title":"Postgraduate Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0490","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00001573-199911000-00007","article-title":"Targets for gene therapy of vein grafts","volume":"14","author":"Newby","year":"1999","journal-title":"Current Opinion in Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0495","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bbi.2006.02.001","article-title":"Ibuprofen use, endotoxemia, inflammation, and plasma cytokines during ultramarathon competition","volume":"20","author":"Nieman","year":"2006","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0500","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of Celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0505","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2125.1998.00718.x","article-title":"Studies with iontophoretic administration of drugs to human dermal vessels in vivo: Cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide","volume":"45","author":"Noon","year":"1998","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0510","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1073\/pnas.85.7.2334","article-title":"Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled","volume":"85","author":"de Nucci","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0515","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1161\/01.ATV.18.12.1922","article-title":"Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells","volume":"18","author":"Okahara","year":"1998","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0520","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1111\/bph.13939","article-title":"Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI2\u202f: A safer alternative to COX-2 inhibition","volume":"174","author":"Ozen","year":"2017","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0525","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/rheumatology\/kep225","article-title":"Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: An evidence-based interpretation","volume":"49","author":"Padol","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0530","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ajcn\/63.2.208","article-title":"Rapid modulation of lung and liver macrophage phospholipid fatty acids in endotoxemic rats by continuous enteral feeding with n-3 and gamma-linolenic fatty acids","volume":"63","author":"Palombo","year":"1996","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0535","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11095-006-9905-5","article-title":"Brain uptake of nonsteroidal anti-inflammatory drugs: Ibuprofen, flurbiprofen, and indomethacin","volume":"23","author":"Parepally","year":"2006","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0540","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0090-6980(81)90135-0","article-title":"Stability of prostaglandin I2 in human blood","volume":"21","author":"Pifer","year":"1981","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0545","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0049-3848(97)00189-8","article-title":"Hyperalphalipoproteinemia and prostaglandin I2 stability","volume":"88","author":"Pirich","year":"1997","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0550","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tcm.2016.04.011","article-title":"FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease","volume":"26","author":"Pirlamarla","year":"2016","journal-title":"Trends in Cardiovascular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0555","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/121390","article-title":"Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders","volume":"2012","author":"Qian","year":"2012","journal-title":"Journal of Aging Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0560","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2131\/jts.44.373","article-title":"Cardio-renal safety of non-steroidal anti-inflammatory drugs","volume":"44","author":"Radi","year":"2019","journal-title":"The Journal of Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0565","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1476-5381.1987.tb11367.x","article-title":"The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide","volume":"92","author":"Radomski","year":"1987","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0570","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1161\/CIRCULATIONAHA.118.033540","article-title":"Cyclooxygenase-2, asymmetric Dimethylarginine, and the cardiovascular Hazard from nonsteroidal anti-inflammatory drugs","volume":"138","author":"Ricciotti","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0575","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/1521-4141(200205)32:5<1482::AID-IMMU1482>3.0.CO;2-O","article-title":"Distinct expression of cyclooxygenase-1 and -2 in the human thymus","volume":"32","author":"Rocca","year":"2002","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0580","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1620\/tjem.231.217","article-title":"Reduced expression of prostacyclin synthase and nitric oxide synthase in subcutaneous arteries of type 2 diabetic patients","volume":"231","author":"Safiah Mokhtar","year":"2013","journal-title":"The Tohoku Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165811","article-title":"Asymmetric and symmetric Dimethylarginine as risk markers for Total mortality and cardiovascular outcomes: A systematic review and meta-analysis of prospective studies","volume":"11","author":"Schlesinger","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0590","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejvs.2016.12.017","article-title":"Investigation of asymmetric and symmetric Dimethylarginine levels after Iloprost treatment in patients with Buerger\u2019s disease","volume":"53","author":"Senol","year":"2017","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0595","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22727-6","article-title":"A novel role of Irbesartan in Gastroprotection against indomethacin-induced gastric injury in rats: Targeting DDAH\/ADMA and EGFR\/ERK Signaling","volume":"8","author":"Shahin","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0600","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/14712598.2014.912272","article-title":"Gene therapy for peripheral arterial disease","volume":"14","author":"Shimamura","year":"2014","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0605","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/gut.43.4.506","article-title":"Intestinal permeability and inflammation in patients on NSAIDs","volume":"43","author":"Sigthorsson","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0610","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0049-3848(90)90025-8","article-title":"Decreased prostaglandin-I2 stability in acute myocardial infarction","volume":"57","author":"Sinzinger","year":"1990","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0615","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0090-6980(87)90118-3","article-title":"Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivo","volume":"33","author":"Sinzinger","year":"1987","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0620","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0262-1746(82)90058-0","article-title":"Central cardiovascular and thermal effects of prostaglandin D2 in rats","volume":"8","author":"Siren","year":"1982","journal-title":"Prostaglandins, Leukotrienes, and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0625","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0024-3205(82)90263-6","article-title":"Differences in the central actions of arachidonic acid and prostaglandin F2 alpha between spontaneously hypertensive and normotensive rats","volume":"30","author":"Siren","year":"1982","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0630","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4137\/BMI.S38434","article-title":"Asymmetric Dimethylarginine and its relation as a biomarker in Nephrologic diseases","volume":"11","author":"Sitar","year":"2016","journal-title":"Biomarker Insights"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0635","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/01616412.1999.11740964","article-title":"Indomethacin: A review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients","volume":"21","author":"Slavik","year":"1999","journal-title":"Neurological Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0640","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/jpet.104.079533","article-title":"Cloning and characterization of cyclooxygenase-1b (putative cyclooxygenase-3) in rat","volume":"313","author":"Snipes","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0645","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1756-185X.2011.01675.x","article-title":"The effect of non-steroidal anti-inflammatory drugs on the endothelial function of patients with osteoarthritis in short term","volume":"15","author":"Solmaz","year":"2012","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0650","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/01.STR.16.1.16","article-title":"Reduction of serum prostacyclin stability in ischemic stroke","volume":"16","author":"Stein","year":"1985","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0655","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17228","article-title":"Trends in prescription analgesic use among adults with musculoskeletal conditions in the United States, 1999-2016","volume":"2","author":"Stokes","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0660","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/CIRCRESAHA.116.308446","article-title":"Heart-brain Axis: Effects of neurologic injury on cardiovascular function","volume":"120","author":"Tahsili-Fahadan","year":"2017","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0665","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jare.2017.11.004","article-title":"Arachidonic acid: Physiological roles and potential health benefits - a review","volume":"11","author":"Tallima","year":"2018","journal-title":"Journal of Advanced Research"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0670","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1161\/CIRCULATIONAHA.113.007913","article-title":"Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice","volume":"129","author":"Tang","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0675","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3233\/JAD-2010-090667","article-title":"Neuroinflammation in Alzheimer\u2019s disease: Are NSAIDs and selective COX-2 inhibitors the next line of therapy?","volume":"21","author":"Trepanier","year":"2010","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0680","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/intimm\/dxt043","article-title":"T cells in atherosclerosis","volume":"25","author":"Tse","year":"2013","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0685","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0690","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/01926230600611752","article-title":"NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression","volume":"34","author":"Tugendreich","year":"2006","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0695","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejim.2015.09.012","article-title":"Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis","volume":"26","author":"Ungprasert","year":"2015","journal-title":"European Journal of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0700","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.91.6.2046","article-title":"Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation","volume":"91","author":"Vane","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0705","first-page":"287","article-title":"COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice","volume":"119","author":"Vardeh","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0710","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2017.09.033","article-title":"Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: A study in adjuvant-induced arthritis","volume":"266","author":"Verhoeven","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0715","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1161\/hc4901.101350","article-title":"Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation","volume":"104","author":"Verma","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0720","doi-asserted-by":"crossref","first-page":"22254","DOI":"10.1074\/jbc.M703169200","article-title":"Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products","volume":"282","author":"Wada","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0725","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00325481.2018.1412799","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited","volume":"130","author":"Walker","year":"2018","journal-title":"Postgraduate Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0730","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/gast.2000.16510","article-title":"NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2","volume":"119","author":"Wallace","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0735","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1161\/CIRCULATIONAHA.110.973685","article-title":"Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury","volume":"123","author":"Wang","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0740","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCULATIONAHA.107.731398","article-title":"Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation","volume":"117","author":"Wang","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0745","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1139\/Y08-003","article-title":"Role of endogenous nitric oxide synthase inhibitor in gastric mucosal injury","volume":"86","author":"Wang","year":"2008","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0750","doi-asserted-by":"crossref","first-page":"14507","DOI":"10.1073\/pnas.0606586103","article-title":"Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis","volume":"103","author":"Wang","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0755","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0760","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.HYP.0000258106.74139.25","article-title":"Cardiovascular effects of the cyclooxygenase inhibitors","volume":"49","author":"White","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0765","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/01.HYP.0000084603.93510.28","article-title":"Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension","volume":"42","author":"Widlansky","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0770","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0735-1097(99)00448-9","article-title":"Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study","volume":"34","author":"Wiedermann","year":"1999","journal-title":"Journal of American College Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0775","first-page":"H171","article-title":"Contribution of prostaglandins to exercise-induced vasodilation in humans","volume":"265","author":"Wilson","year":"1993","journal-title":"The American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0780","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1172\/JCI111670","article-title":"Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura","volume":"75","author":"Wu","year":"1985","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0785","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11906-999-0029-2","article-title":"The role of the central nervous system in hypertension","volume":"1","author":"Wyss","year":"1999","journal-title":"Current Hypertension Reports"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107624_bb0790","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1538-7836.2009.03439.x","article-title":"The translational therapeutics of prostaglandin inhibition in atherothrombosis","volume":"7","author":"Yu","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0795","doi-asserted-by":"crossref","first-page":"132ra154","DOI":"10.1126\/scitranslmed.3003787","article-title":"Vascular COX-2 modulates blood pressure and thrombosis in mice","volume":"4","author":"Yu","year":"2012","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0800","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1172\/JCI113682","article-title":"Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I","volume":"82","author":"Yui","year":"1988","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0805","doi-asserted-by":"crossref","first-page":"R916","DOI":"10.1152\/ajpregu.00406.2002","article-title":"Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: The role of central prostaglandins","volume":"284","author":"Zhang","year":"2003","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0810","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1172\/JCI81550","article-title":"Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertension","volume":"125","author":"Zhang","year":"2015","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107624_bb0815","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1111\/j.1582-4934.2008.00430.x","article-title":"Cyclooxygenase in normal human tissues--is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?","volume":"13","author":"Zidar","year":"2009","journal-title":"Journal of Cellular and Molecular Medicine"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:08:02Z","timestamp":1759010882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820301546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":163,"alternative-id":["S0163725820301546"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107624","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclooxygenases and the cardiovascular system","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107624"}}